The phase III PHOENYCS GO study evaluating BIIB and UCB's drug candidate, dapirolizumab pegol, for treating systemic lupus ...

Biogen and Belgian partner UCB said on Tuesday their experimental lupus treatment met the main goal of a late-stage trial in ...

Gazyva is also being studied in children and adolescents with lupus nephritis and patients with membranous nephropathy, ...

As usual, a second trial will be needed before UCB and Biogen can file dapirolizumab pegol with regulators. It will be called ...

New biologics such as GSK's Benlysta and AstraZeneca's Saphnelo, along with off-label drugs, have been the mainstay for systemic lupus erythematosus (SLE) treatment for many years. However ...

GSK estimates that around 60% of the 300,000-plus severe SLE patients in the US suffer from lupus nephritis each year, and a quarter of those develop end-stage renal disease.

A U.S. judge ruled that Regeneron Pharmaceuticals cannot immediately block U.S. sales of a proposed copy of its blockbuster ...

Approved treatments include AstraZeneca's Saphnelo and GSK's Benlysta ... is being tested in patients with the most common form of lupus, systemic lupus erythematosus, where the patient's ...

while GSK's Benlysta, which first gained approval in 2011, brought in 1.35 billion euros ($1.50 billion) last year. Several other drugmakers are also developing experimental lupus drugs.

The companies now plan on starting this year another large study of their medicine, dapirolizumab pegol, in the hopes that they can confirm its safety and effectiveness to drug regulators.